Hi-Tech Pharmaceuticals v. Ironmag Labs: Topical Androgen Cream Patent Dispute Settles
Hi-Tech Pharmaceuticals and Intellectual Wellness sued Ironmag Labs and its principal Robert Dimaggio over three patents covering topical androgen cream formulations, targeting products including Gear Cream and Lean AF Cream. The case settled after 876 days before Judge J. P. Boulee in the Northern District of Georgia.
Three androgen cream patents at the centre of a sports supplement IP dispute
On 20 June 2022, Hi-Tech Pharmaceuticals, Inc. and affiliated entity Intellectual Wellness, LLC filed suit in the Northern District of Georgia against Ironmag Labs, LLC and its principal Robert Dimaggio. The complaint asserted infringement of three US patents — US8338399B2, US8778918B2, and US8580774B2 — all directed to topical cream formulations in the androgen/prohormone supplement space. The accused products included Gear Cream, Lean AF Cream, Super 1-Andro Cream, and Super 4-Andro Cream.
The case resolved without a merits ruling. On 12 November 2024, the parties filed a Joint Motion to Stay, informing Judge Boulee that the matter had settled. The court administratively closed the case and ordered the parties to file appropriate disposal documents within sixty days. The order expressly noted that administrative closure would not prejudice either party’s rights, consistent with a negotiated resolution rather than a contested dismissal.
At 876 days, the case ran for nearly two and a half years before settlement — a duration suggesting meaningful claim construction or discovery activity before the parties reached agreement. The specific financial terms, licensing arrangements, and any product modifications agreed upon are not reflected in the public docket. The fact that both a company and its named principal were defendants is consistent with plaintiffs seeking to pierce potential corporate liability shields, a pattern sometimes seen in smaller supplement-company disputes.
Filing to Case Stayed in 876 days
876 days — nearly 2.5 years from filing to administrative closure on settlement
Case settles: what the joint motion and administrative closure mean for both parties
Administrative closure on settlement — not a dismissal on the merits
An administrative closure following a joint settlement motion is a procedural tool that removes the case from the active docket without issuing a final judgment. The court retains jurisdiction, and the parties have sixty days to file formal disposal documents. If they fail to do so, the court may dismiss with prejudice. This structure is consistent with parties finalising confidential settlement terms after reaching agreement in principle.
Procedural settlement closurePublic record is silent on whether dismissal will be with or without prejudice
The administrative closure order notes the court may ultimately dismiss with prejudice if no reopening motion is filed within sixty days — but the final disposal documents, typically a stipulated dismissal, had not been publicly filed at closure. A with-prejudice dismissal bars refiling on the same claims; a without-prejudice dismissal does not. The distinction is commercially significant for the patent holder’s future enforcement options against these specific defendants.
Prejudice status: public record silentHi-Tech and Intellectual Wellness secured a negotiated exit without validity risk
By settling before any claim construction ruling or dispositive motion, the patent holders avoided a public finding that could undermine the validity or scope of US8338399B2, US8778918B2, or US8580774B2. Settlement at this stage preserves all three patents for future enforcement against other parties. Any licence terms, royalty obligations, or product discontinuation requirements agreed with Ironmag Labs remain confidential.
Patents preserved for future enforcementIronmag Labs avoids adverse judgment but faces confidential settlement obligations
Settlement means Ironmag Labs and Robert Dimaggio avoided a public infringement finding and any court-ordered injunction or damages award. However, the personal naming of Dimaggio alongside the LLC suggests the plaintiffs applied significant pressure at the individual level. The specific product — Gear Cream, Lean AF Cream, and Andro Cream lines — may be subject to undisclosed licence fees, reformulation requirements, or market exit terms under the settlement agreement.
No public infringement findingFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Hi-Tech Pharmaceuticals, Inc. | Company | Dietary supplement and pharmaceutical company — holder of US8338399B2, US8778918B2, and US8580774B2Search in Eureka ↗ |
| Co-Plaintiff | Intellectual Wellness, LLC | Company | Search in Eureka ↗ |
| Defendant | Ironmag Labs, LLC | Company | Sports supplement brand and its principal, accused of infringing topical androgen cream formulation patentsSearch in Eureka ↗ |
| Co-Defendant | Robert Dimaggio | Individual | Search in Eureka ↗ |
| Plaintiff counsel | Arthur W. Leach | Attorney | Counsel for Hi-Tech Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Gregory Hillyer | Attorney | Counsel for Hi-Tech Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Jessica Leach | Attorney | Counsel for Hi-Tech Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Nicholas John Sullivan | Attorney | Counsel for Hi-Tech Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Hillyer Legal PLLC | Law Firm | Representing Hi-Tech Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff law firm | The Law Office of Arthur W. Leach | Law Firm | Representing Hi-Tech Pharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant counsel | David Alan Reed | Attorney | Counsel for Ironmag Labs, LLCSearch in Eureka ↗ |
| Defendant counsel | Marianthi Marcella Karas | Attorney | Counsel for Ironmag Labs, LLCSearch in Eureka ↗ |
| Defendant counsel | Michael E. Furrow | Attorney | Counsel for Ironmag Labs, LLCSearch in Eureka ↗ |
| Defendant law firm | Kilpatrick Stockton, LLP-NY | Law Firm | Representing Ironmag Labs, LLCSearch in Eureka ↗ |
| Defendant law firm | Kilpatrick Townsend & Stockton LLP (ATL) | Law Firm | Representing Ironmag Labs, LLCSearch in Eureka ↗ |
| Presiding judge | Judge J. P. Boulee | Judge | Georgia Northern District CourtSearch in Eureka ↗ |
Official order — verbatim text
The court’s order reflects a standard administrative closure mechanism used in the N.D. Georgia when parties confirm settlement before final documentation is complete. The language — ‘this matter has settled’ — confirms agreement in principle but stops short of a final dismissal. The sixty-day window and the express possibility of a with-prejudice dismissal absent further filings are procedural safeguards, not substantive findings. Neither party obtained a merits ruling, meaning patent validity, claim scope, and infringement findings all remain open questions on the public record.
US8338399B2, US8778918B2 & US8580774B2 — Topical Androgen Cream Formulations
The three asserted patents — US8338399B2, US8778918B2, and US8580774B2 — appear to cover topical cream formulations designed to deliver androgen and prohormone compounds transdermally, a modality used in the sports supplement and performance nutrition sector. The application numbers (filed under US13/160061, US14/050050, and US13/571434) suggest a family of related filings developed over multiple prosecution cycles, consistent with Hi-Tech’s strategy of building layered protection around a core delivery technology.
In the competitive sports supplement market, transdermal delivery of androgen precursors represents a niche but commercially sensitive category. A portfolio of three overlapping formulation patents, if valid and broadly construed, could effectively foreclose competitors from the topical androgen cream format without a licence. The fact that Hi-Tech and Intellectual Wellness jointly hold enforcement rights suggests a deliberate IP structuring arrangement, potentially separating the holding entity from the operating company to manage enforcement risk.
Should your R&D team run an FTO against US8338399B2, US8778918B2, and US8580774B2?
Any company developing or commercialising topical cream products containing androgen, prohormone, or structurally related compounds should treat this three-patent cluster as a priority FTO target. The accused products in this case — Gear Cream, Lean AF Cream, Super 1-Andro Cream, and Super 4-Andro Cream — indicate the patents cover commercially available transdermal supplement formats. Settlement without a public claim construction means the precise boundaries of these patents remain uncertain, making independent FTO analysis essential before launch.
PatSnap Eureka’s FTO Search Agent can map each claim of US8338399B2, US8778918B2, and US8580774B2 against your specific formulation, identify prior art that could support an IPR petition, and flag design-around opportunities. Given that claim scope has never been judicially tested, early-stage FTO analysis could reveal actionable differences between your formulation and the patents’ coverage — or identify the most vulnerable claims for inter partes review before Hi-Tech initiates enforcement.
Run a freedom-to-operate analysis on US8338399B2 to assess your product’s exposure
Run FTO in Eureka →Similar topical formulation patent cases in N.D. Georgia and the supplement sector
Cases involving transdermal androgen or prohormone formulation patents in N.D. Georgia and comparable supplement IP enforcement actions across US district courts.
What this case signals for the sports supplement IP landscape
Three overlapping formulation patents and named individual defendants signal an aggressive enforcement posture in the topical androgen supplement sector.
Naming principals alongside LLCs is a deliberate enforcement pressure tactic
Including Robert Dimaggio personally alongside Ironmag Labs LLC is consistent with a strategy to maximise settlement leverage. Smaller supplement brands often operate through thinly capitalised LLCs; suing the individual operator raises personal liability exposure and typically accelerates resolution. IP teams at Hi-Tech have demonstrated willingness to pursue this approach in the N.D. Georgia forum.
Three-patent assertion creates a broad formulation moat around topical androgen delivery
Asserting US8338399B2, US8778918B2, and US8580774B2 simultaneously suggests Hi-Tech and Intellectual Wellness have constructed a layered IP position covering multiple aspects of topical androgen/prohormone cream technology. Competitors in this product category should treat these three patents as a cluster requiring independent FTO analysis, not individual clearance.
Hi-Tech v Ironmag — key questions answered
Hi-Tech Pharmaceuticals and Intellectual Wellness asserted three patents: US8338399B2, US8778918B2, and US8580774B2. All three cover topical androgen and prohormone cream formulations. The accused products were Gear Cream, Lean AF Cream, Super 1-Andro Cream, and Super 4-Andro Cream marketed by Ironmag Labs.
The case resolved by settlement, not a merits judgment. On 12 November 2024, the parties filed a Joint Motion to Stay informing the court of settlement. Judge Boulee administratively closed the docket. No claim construction, validity, or infringement ruling was issued. Settlement terms are confidential and not reflected in the public record.
Administrative closure is a docket management tool, not a final judgment. The court retains jurisdiction, and Hi-Tech’s patent rights remain intact. The court ordered disposal documents within sixty days; absent those, dismissal with prejudice was possible. The public record does not confirm the final dismissal terms, meaning the prejudice status of any subsequent refiling against these defendants is technically unclear.
Naming an individual principal alongside the operating entity is consistent with a strategy to create personal liability exposure and maximise settlement pressure, particularly where the defendant company may be thinly capitalised. The public record does not specify which acts Dimaggio was individually alleged to have committed, but this approach is a recognised enforcement tactic in smaller-company IP disputes.
The three asserted patents — US8338399B2, US8778918B2, and US8580774B2 — have never had their claims judicially construed, meaning their precise scope is uncertain. Competitors developing topical androgen or prohormone cream formulations should conduct independent FTO analysis against all three patents. Because the case settled before any Markman ruling, there is no public claim construction that narrows or limits enforcement risk.
PatSnap Eureka searches patents and litigation data to answer instantly.